Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
Kohei KakuKazuyuki IshidaKohei ShimizuMeguru AchiraYuusuke UmedaPublished in: Journal of diabetes investigation (2019)
Once-weekly trelagliptin 25 mg was efficacious, with no major safety concerns, and represents a meaningful treatment option in this patient population.